|
1.
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2.
|
Brambilla E: [Classification of
broncho-pulmonary cancers (WHO 1999)]. Rev Mal Respir. 19:455–466.
2002.(In French).
|
|
3.
|
Varlotto JM, Medford-Davis LN, Recht A, et
al: Should large cell neuroendocrine lung carcinoma be classified
and treated as a small cell lung cancer or with other large cell
carcinomas? J Thorac Oncol. 6:1050–1058. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Sun JM, Ahn MJ, Ahn JS, et al:
Chemotherapy for pulmonary large cell neuroendocrine carcinoma:
similar to that for small cell lung cancer or non-small cell lung
cancer? Lung Cancer. 77:365–370. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Swarts DRA, Ramaekers FCS and Speel E-JM:
Molecular and cellular biology of neuroendocrine lung tumors:
evidence for separate biological entities. Biochim Biophys Acta.
1826:255–271. 2012.PubMed/NCBI
|
|
6.
|
Duvic M, Talpur R, Ni X, et al: Phase 2
trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA)
for refractory cutaneous T-cell lymphoma (CTCL). Blood. 109:31–39.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Olsen EA, Kim YH, Kuzel TM, et al: Phase
IIb multicenter trial of vorinostat in patients with persistent,
progressive, or treatment refractory cutaneous T-cell lymphoma. J
Clin Oncol. 25:3109–3115. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Marchion D and Munster P: Development of
histone deacetylase inhibitors for cancer treatment. Expert Rev
Anticancer Ther. 7:583–598. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Fiskus W, Hembruff SL, Rao R, et al:
Co-treatment with vorinostat synergistically enhances activity of
Aurora kinase inhibitor against human breast cancer cells. Breast
Cancer Res Treat. 135:433–444. 2012. View Article : Google Scholar
|
|
10.
|
Lautz TB, Jie C, Clark S, et al: The
effect of vorinostat on the development of resistance to
doxorubicin in neuroblastoma. PLoS One. 7:e408162012. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Muscal JA, Scorsone KA, Zhang L, Ecsedy JA
and Berg SL: Additive effects of vorinostat and MLN8237 in
pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.
Invest New Drugs. 31:39–45. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Karelia N, Desai D, Hengst JA, Amin S,
Rudrabhatla SV and Yun J: Selenium-containing analogs of SAHA
induce cytotoxicity in lung cancer cells. Bioorg Med Chem Lett.
20:6816–6819. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Witta S: Histone deacetylase inhibitors in
non-small-cell lung cancer. J Thorac Oncol. 7:S404–S406. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Kovacic P and Edwards CL: Hydroxamic acids
(therapeutics and mechanism): chemistry, acyl nitroso, nitroxyl,
reactive oxygen species, and cell signaling. J Recept Signal
Transduct Res. 31:10–19. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Osada H: ASH1 gene is a specific
therapeutic target for lung cancers with neuroendocrine features.
Cancer Res. 65:10680–10685. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Lee M, Draoui M, Zia F, et al: Epidermal
growth factor receptor monoclonal antibodies inhibit the growth of
lung cancer cell lines. J Natl Cancer Inst Monogr. 117–123.
1992.PubMed/NCBI
|
|
17.
|
Backs J and Olson EN: Control of cardiac
growth by histone acetylation/deacetylation. Circ Res. 98:15–24.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Rangwala S, Zhang C and Duvic M: HDAC
inhibitors for the treatment of cutaneous T-cell lymphomas. Future
Med Chem. 4:471–486. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Marks PA: Discovery and development of
SAHA as an anticancer agent. Oncogene. 26:1351–1356. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
New M, Olzscha H and La Thangue NB: HDAC
inhibitor-based therapies: can we interpret the code? Mol Oncol.
6:637–656. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Khan O and La Thangue NB: HDAC inhibitors
in cancer biology: emerging mechanisms and clinical applications.
Immunol Cell Biol. 90:85–94. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Fernandez FG and Battafarano RJ:
Large-cell neuroendocrine carcinoma of the lung. Cancer Control.
13:270–275. 2006.PubMed/NCBI
|
|
23.
|
Gollard R, Jhatakia S, Elliott M and Kosty
M: Large cell/neuroendocrine carcinoma. Lung Cancer. 69:13–18.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Worster DT, Schmelzle T, Solimini NL, et
al: Akt and ERK control the proliferative response of mammary
epithelial cells to the growth factors IGF-1 and EGF through the
cell cycle inhibitor p57Kip2. Sci Signal. 5:ra192012.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Shaw RJ and Cantley LC: Ras, PI(3)K and
mTOR signalling controls tumour cell growth. Nature. 441:424–430.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Hsieh AC, Truitt ML and Ruggero D:
Oncogenic AKTivation of translation as a therapeutic target. Br J
Cancer. 105:329–336. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Engelman JA: Targeting PI3K signalling in
cancer: opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Cagnol S and Chambard JC: ERK and cell
death: mechanisms of ERK-induced cell death - apoptosis, autophagy
and senescence. FEBS J. 277:2–21. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Hanahan D and Folkman J: Patterns and
emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Carmeliet P, Dor Y, Herbert JM, et al:
Role of HIF-1alpha in hypoxia-mediated apoptosis, cell
proliferation and tumour angiogenesis. Nature. 394:485–490. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Semenza GL: Evaluation of HIF-1 inhibitors
as anticancer agents. Drug Discov Today. 12:853–859. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar
|
|
34.
|
Muhlethaler-Mottet A, Meier R, Flahaut M,
et al: Complex molecular mechanisms cooperate to mediate histone
deacetylase inhibitors anti-tumour activity in neuroblastoma cells.
Mol Cancer. 7:552008. View Article : Google Scholar
|
|
35.
|
Shankar S, Davis R, Singh KP, Kurzrock R,
Ross DD and Srivastava RK: Suberoylanilide hydroxamic acid
(Zolinza/ vorinostat) sensitizes TRAIL-resistant breast cancer
cells orthotopically implanted in BALB/c nude mice. Mol Cancer
Ther. 8:1596–1605. 2009. View Article : Google Scholar
|
